** Shares of cell therapy developer BioCardia rise 17.3% to $5.12 premarket
** Co says it has received a U.S. patent for its heart device, which will expire in 2036
** The patent relates to a radial artery delivery system, by which cardiac catheters are placed through a blood vessel in a patient's wrist to treat the heart
** Co says its delivery systems are designed to prevent leakage of therapeutic agents by providing stable and safe engagement to the heart tissue during the delivery process
** Up to last close, stock is down 56.2% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments